20 questions answered from cited research · Plain language
Yes, SGLT2 inhibitors are effective for treating heart failure with mildly reduced ejection fraction, reducing heart failure hospitalizations and improving outcomes.
Read the full answer →Yes, finerenone reduces cardiovascular death and worsening heart failure events in patients with heart failure with mildly reduced ejection fraction, based on a network meta-analysis and the FINEARTS-HF trial.
Read the full answer →Erythropoiesis-stimulating agents (ESAs) reduce total heart failure hospitalizations and improve exercise tolerance in adults with chronic heart failure and anaemia, but do not lower mortality risk.
Read the full answer →No, alternative loop diuretics (torsemide, azosemide, piretanide) do not reduce hospitalizations compared to furosemide in chronic heart failure, based on a systematic review of 23 trials.
Read the full answer →Coping experiences for CHF patients and caregivers center on differing views of illness, emotional exhaustion, strained relationships, and a need for support to find new meaning.
Read the full answer →A 2024 trial found that adding Qishen Yiqi dropping pills to standard Western medicine improved clinical effectiveness and heart function in chronic heart failure patients.
Read the full answer →Higher EPA levels may slightly increase ischemic heart disease risk, according to genetic studies, but the evidence is not definitive.
Read the full answer →Levosimendan improves symptoms and heart function in acute heart failure, but can cause hypotension and tachycardia; benefits may vary by BMI.
Read the full answer →Yes, high GDF-15 levels in the blood are strongly linked to a higher risk of death in acute heart failure patients, with a meta-analysis showing nearly three times the risk.
Read the full answer →Yes, heart disease was the second leading cause of death in the US in 2021, ranking behind only COVID-19.
Read the full answer →In US adults aged 45 to 64, heart disease and cancer are the two leading causes of death, with heart disease deaths slightly exceeding cancer deaths during the 1999–2018 period.
Read the full answer →Yes, imaging heart muscle strain (speckle-tracking echocardiography) can detect early heart dysfunction in children with congenital heart disease, helping guide treatment and predict outcomes better than standard tests alone.
Read the full answer →Yes, surgery with a heart-lung machine can cause low oxygen levels in the brains of babies with congenital heart disease, especially in the early postoperative period.
Read the full answer →Yes, non-traditional lipid indices like Castelli risk index-II (CRI-II) and triglyceride-rich lipoprotein cholesterol (TRL-C) are associated with coronary heart disease risk in people with diabetes, and may improve risk prediction beyond standard cholesterol tests.
Read the full answer →The Systemic Immune-Inflammation Index (SII) is a blood test marker that combines platelet, neutrophil, and lymphocyte counts to measure inflammation. Higher SII levels are linked to higher coronary heart disease risk, especially in acute cases and in people with diabetes.
Read the full answer →Periodontitis is linked to a higher risk of coronary heart disease, likely due to chronic inflammation, but a direct cause has not been proven.
Read the full answer →Yes, exercise-based cardiac rehabilitation significantly reduces hospitalizations for coronary heart disease, according to multiple meta-analyses.
Read the full answer →Yes, routine clinical indicators like blood pressure, cholesterol, blood sugar, and inflammatory markers can predict your coronary heart disease risk with good accuracy.
Read the full answer →SGLT-2 inhibitors (like empagliflozin, dapagliflozin) are the most effective glucose-lowering therapies for heart failure in type 2 diabetes, reducing hospitalizations and cardiovascular death.
Read the full answer →Yes, a new valve procedure (TAVR or TTVR) can reduce heart failure hospitalizations in certain patients, based on recent trials.
Read the full answer →